Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/19/2021 11/22/2021 11/23/2021 11/24/2021 11/26/2021 Date
183.62(c) 176.12(c) 173.82(c) 173.2(c) 169.5(c) Last
796 228 865 031 992 568 822 863 735 621 Volume
-0.32% -4.08% -1.31% -0.36% -2.14% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 549 M - -
Net income 2021 -647 M - -
Net cash position 2021 2 361 M - -
P/E ratio 2021 -47,5x
Yield 2021 -
Sales 2022 2 187 M - -
Net income 2022 -161 M - -
Net cash position 2022 2 160 M - -
P/E ratio 2022 -206x
Yield 2022 -
Capitalization 30 994 M 30 994 M -
EV / Sales 2021 18,5x
EV / Sales 2022 13,2x
Nbr of Employees 2 092
Free-Float 99,3%
More Financials
Company
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in the development and sale of pharmaceutical products on its own, behalf or in collaboration with others. The Company is commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV or enfortumab vedotin-ejfv, for the treatment of... 
Read more
Sector
Biotechnology & Medical Research
Calendar
12/08 | 08:00amPresentation
More about the company
Ratings of Seagen Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about SEAGEN INC.
11/24SEAGEN : Material Event - Form 8-K
PU
11/24SEAGEN INC. : Other Events (form 8-K)
AQ
11/19Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cance..
BU
11/19Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cance..
CI
11/15INSIDER SELL : Seagen
MT
11/09Wolfe Research Starts Seagen at Peer Perform With $195 Price Target
MT
11/09Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual M..
BU
11/09Seagen to Highlight Two Novel Antibody-Drug Conjugates at the SITC 36th Annual Meeting
CI
11/08INSIDER SELL : Seagen
MT
11/04Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the ..
BU
11/04Seagen Inc. to Highlight Multiple ADCETRIS? (brentuximab vedotin) Data Presentations at..
CI
11/03INSIDER SELL : Seagen
MT
10/29Oppenheimer Adjusts Seagen PT to $198 From $196, Maintains Outperform Rating
MT
10/29Morgan Stanley Adjusts Price Target on Seagen to $181 From $167, Maintains Equal-Weight..
MT
10/29Q3 2021 Earnings Call Corrected Transcript
PU
More news
News in other languages on SEAGEN INC.
11/15VENTE PAR UN INITIÉ : Seagen
11/08VENTE PAR UN INITIÉ : Seagen
11/03VENTE PAR UN INITIÉ : Seagen
10/28Seagen enregistre une perte au troisième trimestre et une baisse du chiffre d'affaires ..
10/28Earnings Flash (SGEN) SEAGEN annonce un chiffre d'affaires de 424,1 millions de dollars..
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Analysis
China's biotech sector comes of age with big licensing deals, global ambitions
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 169,50 $
Average target price 190,05 $
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
Clay B. Siegall Chairman, President & Chief Executive Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-3.22%30 994
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
CELLTRION, INC.-40.39%24 431
ALNYLAM PHARMACEUTICALS, INC.45.06%22 548